Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
Do you obtain somatic genomic testing for ovarian cancer patients that test negative for gBRCA mutation?
Answer from: at Academic Institution
Yes. There are patients who will have somatic BRCA mutations, but not germ line mutations.
Sign in or Register to read more
7721
Related Questions
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
What are your top takeaways in Gyn Cancers from ESMO 2024?
How do you manage patients with germline BRCA mutations who have STIC lesions found at time of risk-reducing BSO?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
For patients with ovarian cancer, do you order folate receptor-alpha testing at initial diagnosis, first recurrence, or first instance of platinum resistance?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
What second-line therapy would you recommend for a patient with a pathogenic BRCA-1 mutation and stage IIIA fallopian tube high-grade serous carcinoma, who underwent R0 cytoreduction followed by 6 cycles of carboplatin/paclitaxel with complete response, who has now progressed 13 months into olaparib maintenance?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?